3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)-5-[(phenylmethyl)oxy]benzamide → (S)-3-hydroxy-5-(1-methoxypropan-2-yloxy)-N-(5-methylpyrazin-2-yl)benzamide
Reaction equation
[CH3:1][C@H:2]([O:6][C:7]1[CH:8]=[C:9]([CH:20]=[C:21]([O:23]CC2C=CC=CC=2)[CH:22]=1)[C:10]([NH:12][C:13]1[CH:18]=[N:17][C:16]([CH3:19])=[CH:15][N:14]=1)=[O:11])[CH2:3][O:4][CH3:5]>[Pd].C(O)C>[OH:23][C:21]1[CH:20]=[C:9]([CH:8]=[C:7]([O:6][C@@H:2]([CH3:1])[CH2:3][O:4][CH3:5])[CH:22]=1)[C:10]([NH:12][C:13]1[CH:18]=[N:17][C:16]([CH3:19])=[CH:15][N:14]=1)=[O:11]Participants
4
Reactant 1
Product 1
Reagents, catalysts & solvents 2
Procedure
10% Palladium on charcoal (700 mg) was added to a solution of 3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)-5-[(phenylmethyl)oxy]benzamide (7.0 g, 17.2 mmol) in ethanol (125 mL) and the mixture stirred at RT under a hydrogen atmosphere for 4 hours. The catalyst was removed by filtration and the ethanol evaporated in vacuo. The residue was crystallised from ethyl acetate to give the desired compound (4.22 g). 1H NMR δ (CDCl3): 1.25 (d, 3H), 2.5 (s, 3H), 3.3 (s, 3H), 3.4-3.5 (m, 2H), 4.5 (m, 1H), 6.3 (br, 1H), 6.55 (s, 1H), 6.9 (s, 1H), 6.95 (s, 1H), 8.05 (s, 1H), 8.45 (s, 1H) and 9.5 (s, 1H). m/z 318 (M+H)+.
Workup
- customThe catalyst was removed by filtration
- customthe ethanol evaporated in vacuo
- customThe residue was crystallised from ethyl acetate
Sources & evidence
- ORD record
- ord-c39045f118f740ff85f2bbc530592300
- Source dataset
- uspto-grants-2011_05
- Patent number
- US07943607B2
Reaction notes
Loading…